TransEnterix (TRXDW) Stock Price, News & Analysis

Company Overview

TransEnterix, trading under the OTCMKTS symbol TRXDW, is a medical device company specializing in the development and commercialization of robotic-assisted surgical systems. Headquartered in Durham, North Carolina, the company focuses on advancing minimally invasive surgery through its proprietary technologies that enhance precision, visualization and control for surgeons.

The company’s flagship offering is the Senhance Surgical Robotic System, which integrates 3D high-definition visualization, haptic feedback and eye-tracking camera control to facilitate complex laparoscopic procedures. Senhance-compatible instruments are designed for single-use or modular reuse, allowing healthcare providers to tailor treatment strategies while potentially reducing overall procedure costs. TransEnterix has positioned Senhance as an alternative to other robotic platforms by emphasizing open console design, customizable instrument architectures and digital data capture.

Founded in 1995, TransEnterix completed its initial public offering in 2013 and has since pursued strategic collaborations to expand clinical applications for its technology. In May 2021, the company rebranded to Asensus Surgical to reflect its emphasis on digital laparoscopy, although it continues to trade under the TransEnterix corporate framework. Over the years, the company has secured regulatory clearances in the United States and received CE Mark approval in Europe, enabling installations in leading medical centers across North America, Europe and select markets in Asia.

Under the leadership of President and Chief Executive Officer Todd M. Pope, TransEnterix continues to invest in R&D and commercial expansion. The company’s sales and support network spans key surgical hubs, and it collaborates with clinical partners to generate real-world evidence on the efficacy and safety of its systems. Moving forward, TransEnterix aims to leverage its digital platform to drive broader adoption of minimally invasive robotic surgery worldwide.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.15 to $0.15
• 52-Week Range: $0.12 to $0.18
• Volume: N/A
• Average Volume: 8,250 shs
• Market Capitalization: $21.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRXDW Stock Analysis - Frequently Asked Questions

How have TRXDW shares performed this year?

TransEnterix's stock was trading at $0.15 at the beginning of 2025. Since then, TRXDW shares have increased by 0.0% and is now trading at $0.15.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (OTCMKTS:TRXDW) announced its earnings results on Thursday, November, 5th. The medical instruments supplier reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.11. The medical instruments supplier earned $0.81 million during the quarter, compared to the consensus estimate of $0.73 million. TransEnterix had a negative net margin of 2,149.15% and a negative trailing twelve-month return on equity of 83.74%.

How do I buy shares of TransEnterix?

Shares of TRXDW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/05/2020
• Today: 9/16/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:TRXDW
• CIK: 876378
• Web: www.transenterix.com
• Phone: +1-919-7658400
• Fax: N/A
• Employees: 170
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($4.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$154.20 million
• Net Margins: -2,149.15%
• Pretax Margin: N/A
• Return on Equity: -83.74%
• Return on Assets: -64.94%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 3.24
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $8.53 million
• Price / Sales: 2.51
• Cash Flow: $0.11 per share
• Price / Cash Flow: 1.40
• Book Value: $2.68 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 142,777,000
• Free Float: N/A
• Market Cap: $21.42 million
• Optionable: Not Optionable
• Beta: 2.56